Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD
Human Gene Therapy · 2024-12 · 35 (23-24) · 969-977
DOI: 10.1089/hum.2024.079 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Human Gene Therapy, online erschienen am 13.12.2024. Verfasst von Xuzhen Qin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The Second Hospital of Shandong University, Ji'nan, China. Hauptthemen laut MEDLINE: Dependovirus, Antibodies, Neutralizing, Muscular Dystrophy, Duchenne, Serogroup. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
To facilitate adeno-associated virus (AAV)-mediated gene therapy in China, we conducted a study on the distribution of AAV-neutralizing antibodies (NAbs) in healthy subjects and in patients with Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD). A total of 352 healthy adult controls (ACs) from a national multicenter study, 100 schoolchild controls (SCs), and 281 patients with DMD/BMD from Peking Union Medical College Hospital were enrolled in this study. Cell-based inhibition assays were applied, and serum samples demonstrating 50% inhibition of infection were considered positive. The seroprevalence of AAV2 and AAV9 NAbs among the 733 participants was 86.1% and 56.3%, respectively. The AAV2 NAbs and AAV9 NAbs positivity rates in the AC, SC, and DMD/BMD groups were 97.4%/86.6%, 100.0%/17.0%, and 66.9%/32.4%, respectively. The seroprevalence of AAV NAbs gradually increased with age, especially in AAV9 NAbs. Females tended to have higher positivity rate than males. Over 85% of ACs had overlapping AAV9 and AAV2 infection. However, being positive for only AAV2 NAbs in the SC group was common, and 30.6% of patients with DMD/BMD were negative for both AAV2 and AAV9 NAbs. Our findings reveal that a significant proportion of patients with DMD/BMD were negative for AAV2 and AAV9 NAbs, which is the population that is most amenable to being treated with gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The Second Hospital of Shandong University, Ji'nan, China.
- Department of Laboratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China.
- Department of Pathogenic Biology, School of Basic Medicine, Peking University, Beijing, China.
- Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China.
- Department of Neurology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China.
ORCID-Profile: Xuzhen Qin
Zitieren
APA
Qin, X., Li, H., Zhao, H., Xiang, K., Liu, S., Lou, R., Liu, P., Dai, Y., Wang, C., & Zhang, S. (2024). Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD. Human Gene Therapy, 35(23-24), 969-977. https://doi.org/10.1089/hum.2024.079
Vancouver
Qin X, Li H, Zhao H, Xiang K, Liu S, Lou R, et al. Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD. Human Gene Therapy. 2024;35(23-24):969-977. doi:10.1089/hum.2024.079
BibTeX
@article{Qin2024,
author = {Qin, Xuzhen and Li, Huan and Zhao, Huiying and Xiang, Kuanhui and Liu, Shihui and Lou, Ruolin and Liu, Peng and Dai, Yi and Wang, Chuanxin and Zhang, Shuyang},
title = {Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD},
journal = {Human Gene Therapy},
year = {2024},
volume = {35},
number = {23-24},
pages = {969--977},
doi = {10.1089/hum.2024.079}
}
EUVIMED